1Pul CH, Pei D, Sandlund JT, et al. Risk of Adverse Events After Completion of Therapy for Childhood Acute Lymphoblastic Leukemia. J Clin Oncol, 2005 ; 23:7936-7941.
2Chauvenet AR, Madin P, Devidas M, et al. Antimetabolite therapy for lesser-risk B-lineage acute lymphoblastic leukemia of childhood: a report from Children' s Oncology Group Study /9201. Blood,2007;110:1105-1111.
3Veerman AJP, Hahlen K, Kamps WA, et al. High Cure Rate With a Moderately Intensive Treatment Regimen in Non-High-Risk Child- hood Acute Lymphoblastic Leukemia: Results of Protocol ALL VI From the Dutch Childhood Leukemia Study Group. J Clin Oncol, 1996; 14:911-918.
4Bostrom BC, Sensei MR, Sather HN, et al. Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children' s Cancer Group. Bloodt 2003 ;101:3809-3817.
5Schrappe M, Reiter A, Zimmermann M, et al. Long - term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Leukemia, 2000 ; 14:2205-2222.
6Moricke A, Reiter A, Zimmermann M, et al. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood, 2008 ; 111:4477-4489.
7Reiter A, Schrappe M, Ludwig WD, et al. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the muhicenter trial ALL-BFM 86. Blood, 1994; 84:3122-3133.
8Hutchinson R J, Gaynon PS, Sather H, et al. Intensification of Therapy for Children With Lower-Risk Acute Lymphoblastic Leukemia: Long-Term Follow-Up of Patients Treated on Children' s Cancer Group Trial 1881. J Clin Oncol, 2003 ; 21 : 1790-1797.
9Seibel NL, Steinherz PO, Sather HN, et al. Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children' s Ontology Group: Blood, 2008 ;111:2548-2555.
10Nachman JB, Sather HN, Sensei MO, et al. Augmented postinduction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. N Engl J Med, 1998;338: 1663-1671.
同被引文献31
1Hunger SP,Lu X,Devidas M,et al. Improved survival for childrenand adolescents with acute lymphoblastic leukemia between 1990and 2005: a report from the children's oncology group. J ClinOncol,2012;30( 14) :1663 -1669.
2Pui CH, Campana D, Pei D, et al. Treating childhood acutelymphoblastic leukemia without cranial irradiation. N Engl J Med,2009;360(26) :2730 -2741.
3Escherich G,Horstmann MA,Zimmermann M,et al. Cooperativestudy group for childhood acute lymphoblastic leukaemia ( CO-ALL) :long-term results of trials 82,85,89,92 and 97. Leukemia,2010;24(2) :298 -308.
4Robison LL. Late effects of acute lymphoblastic leukemia therapy inpatients diagnosed at 0 - 20 years of age. Hematology Am SocHematol Educ Program,2011 ; 2011:238 -242.
5Freyer DR, Devidas M, La M, et al. Postrelapse survival inchildhood acute lymphoblastic leukemia is independent of initialtreatment intensity : a report from the Children *s Oncology Group.Blood,2011;117(11) :3010 -3015.
6Conklin HM, Krull KR, Reddick WE, et al. Cognitive outcomesfollowing contemporary treatment without cranial irradiation forchildhood acute lymphoblastic leukemia. J Natl Cancer Inst, 2012 ;104(18) :1386 -1395.
7Chanvenet AR,Madin P, Devidas M,et al. Antimelabolite therapyfor lesser-risk B-lineage Acute lymphoblastic leukemia of child-hood :a report from Children' s Oncology Group Study P9201.Blood,2007; 110(4) :1105-1111.
8Moricke A,Reiter A, Zimmermann M,et al. Risk-adjust therapy ofacute lymphoblastic leukemia can decrease treatment burden andimprove survival : treatment results of 2169 unselected pediatric andadolescent patients enrolled in the trial ALL-BFM 95. Blood,2008 ;111(9) :4477 -4489.
10Dunsmore KP, Devidas M, Linda SB,et al. Pilot study of nelarabinein combination with intensive chemotherapy in high-risk T-cellacute lymphoblastic leukemia : a report from the Children' sOncology Group. J Clin Oncol,2012;30(22) :2753 -2759.
